The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | LDS1 as a potential target in SCLC
Small cell lung cancer (SCLC) is an aggressive form of lung cancer and immunotherapy as a treatment option remains limited due to downregulation of major histocompatibility complex (MHC) class I molecules. Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, describes ongoing research relating to lysine-specific histone demethylase 1A (LSD1), which is found to be upregulated in cancer cells. In vitro and animal models have shown that inhibition of LDS1 upregulates MHC class I expression and antigen presentation, improving the anti-tumor response. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
